NeuroStar TMS Receives Expanded Regulatory Approval in Japan
The features covered in this approval include the NeuroStar 3.7 platform, MT Cap , D-Tect ™ MT Accessory, and the Dash treatment protocol.
- The features covered in this approval include the NeuroStar 3.7 platform, MT Cap , D-Tect ™ MT Accessory, and the Dash treatment protocol.
- The Dash treatment protocol reduces the daily TMS treatment time from 38 minutes to under 19 minutes.
- NeuroStar TMS Therapy aims to fill this unmet need through its exclusive distribution partnership with Teijin Pharma Limited.
- NeuroStar is advancing its global strategy and strengthening its global presence with recent announcements of regulatory approval in South Korea , as well as EU-MDR and MDSAP certifications.